Abstract

Rituximab was the first monoclonal antibody used for the treatment of a malignancy. In the 22 years since initial approval, it has become a vital component of therapy for a multitude of B-cell malignancies. Within the last several years, however, there has been a robust development of novel agents targeting CD20, including second generation anti-CD20 antibodies, biosimilar antibodies, and subcutaneous formulations that have been approved. The era of passive immunotherapy is now yielding to therapeutic approaches that actively engage the immune system. Emerging approaches leverage immunomodulatory drugs or novel checkpoint inhibitors to enhance CD20 therapy. Recent data sets on bispecific CD3/CD20 antibodies demonstrate exciting early findings, and CD20-directed chimeric antigen receptor T-cell therapies are now entering clinical trials. Anti-CD20 therapies are a vital component of the treatment of B-cell malignancies, and there is a dynamic therapeutic environment with multiple new data sets reviewed here.

References

References
1.
Stashenko
P
,
Nadler
LM
,
Hardy
R
,
Schlossman
SF
.
Characterization of a human B lymphocyte-specific antigen
.
J Immunol
.
1980
;
125
(
4
):
1678
-
1685
.
2.
Termini
CM
,
Gillette
JM
.
tetraspanins function as regulators of cellular signaling
.
Front Cell Dev Biol
.
2017
;
5
:
34
.
3.
Polyak
MJ
,
Li
H
,
Shariat
N
,
Deans
JP
.
CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins
.
J Biol Chem
.
2008
;
283
(
27
):
18545
-
18552
.
4.
Bonavida
B
.
What signals are generated by anti-CD20 antibody therapy?
Curr Hematol Malig Rep
.
2006
;
1
(
4
):
205
-
213
.
5.
Marshall
MJE
,
Stopforth
RJ
,
Cragg
MS
.
Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?
Front Immunol
.
2017
;
8
:
1245
.
6.
McLaughlin
P
,
Grillo-López
AJ
,
Link
BK
, et al
.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
.
J Clin Oncol
.
1998
;
16
(
8
):
2825
-
2833
.
7.
Green
DJ
,
Press
OW
.
Whither radioimmunotherapy: to be or not to be?
Cancer Res
.
2017
;
77
(
9
):
2191
-
2196
.
8.
Rizzieri
D
.
Zevalin(®) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned?
Crit Rev Oncol Hematol
.
2016
;
105
:
5
-
17
.
9.
Osterborg
A
.
Ofatumumab, a human anti-CD20 monoclonal antibody
.
Expert Opin Biol Ther
.
2010
;
10
(
3
):
439
-
449
.
10.
Wierda
WG
,
Kipps
TJ
,
Mayer
J
, et al
;
Hx-CD20-406 Study Investigators
.
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
.
J Clin Oncol
.
2010
;
28
(
10
):
1749
-
1755
.
11.
Hillmen
P
,
Robak
T
,
Janssens
A
, et al
;
COMPLEMENT 1 Study Investigators
.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
.
Lancet
.
2015
;
385
(
9980
):
1873
-
1883
.
12.
Robak
T
,
Warzocha
K
,
Govind Babu
K
, et al
.
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
.
Leuk Lymphoma
.
2017
;
58
(
5
):
1084
-
1093
.
13.
van Oers
MHJ
,
Kuliczkowski
K
,
Smolej
L
, et al
;
PROLONG study investigators
.
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
.
Lancet Oncol
.
2015
;
16
(
13
):
1370
-
1379
.
14.
van Imhoff
GW
,
McMillan
A
,
Matasar
MJ
, et al
.
Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study
.
J Clin Oncol
.
2017
;
35
(
5
):
544
-
551
.
15.
Beers
SA
,
French
RR
,
Chan
HTC
, et al
.
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
.
Blood
.
2010
;
115
(
25
):
5191
-
5201
.
16.
Valgardsdottir
R
,
Cattaneo
I
,
Klein
C
,
Introna
M
,
Figliuzzi
M
,
Golay
J
.
Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies
.
Blood
.
2017
;
129
(
19
):
2636
-
2644
.
17.
Awasthi
A
,
Rolland
DCM
,
Ayello
J
, et al
.
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment
.
Oncotarget
.
2017
;
8
(
69
):
113895
-
113909
.
18.
Alduaij
W
,
Ivanov
A
,
Honeychurch
J
, et al
.
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
.
Blood
.
2011
;
117
(
17
):
4519
-
4529
.
19.
Latour
S
,
Zanese
M
,
Le Morvan
V
, et al
.
Role of calcium signaling in GA101-induced cell death in malignant human B cells
.
Cancers (Basel)
.
2019
;
11
(
3
):
E291
.
20.
Honeychurch
J
,
Alduaij
W
,
Azizyan
M
, et al
.
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
.
Blood
.
2012
;
119
(
15
):
3523
-
3533
.
21.
Shields
RL
,
Lai
J
,
Keck
R
, et al
.
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity
.
J Biol Chem
.
2002
;
277
(
30
):
26733
-
26740
.
22.
Shinkawa
T
,
Nakamura
K
,
Yamane
N
, et al
.
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
.
J Biol Chem
.
2003
;
278
(
5
):
3466
-
3473
.
23.
Liu
SD
,
Chalouni
C
,
Young
JC
,
Junttila
TT
,
Sliwkowski
MX
,
Lowe
JB
.
Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC
.
Cancer Immunol Res
.
2015
;
3
(
2
):
173
-
183
.
24.
Babiker
HM
,
Glode
AE
,
Cooke
LS
,
Mahadevan
D
.
Ublituximab for the treatment of CD20 positive B-cell malignancies
.
Expert Opin Investig Drugs
.
2018
;
27
(
4
):
407
-
412
.
25.
Goede
V
,
Fischer
K
,
Busch
R
, et al
.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
.
N Engl J Med
.
2014
;
370
(
12
):
1101
-
1110
.
26.
Goede
V
,
Fischer
K
,
Dyer
MJS
, et al
.
Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study
.
EHA Learning Center
.
2018
;
15
:
215923
.
27.
Marcus
R
,
Davies
A
,
Ando
K
, et al
.
Obinutuzumab for the first-line treatment of follicular lymphoma
.
N Engl J Med
.
2017
;
377
(
14
):
1331
-
1344
.
28.
Seymour
JF
,
Marcus
R
,
Davies
A
, et al
.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
.
Haematologica
.
2019
;
104
(
6
):
1202
-
1208
.
29.
Mistry
B
,
Launonen
A
,
Tsuchiya
C
,
Cameron
H
,
Thuresson
PO
.
Obinutuzumab in previously untreated follicular lymphoma: an important clinical and cost-effective option for high-risk (intermediate/high FLIPI) patients in Canada [abstract]
.
Value Health
.
2019
;
22
(
suppl 2
):
S75
.
Abstract PCN104
.
30.
Sehn
LH
,
Chua
N
,
Mayer
J
, et al
.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
.
Lancet Oncol
.
2016
;
17
(
8
):
1081
-
1093
.
31.
Cheson
BD
,
Chua
N
,
Mayer
J
, et al
.
Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study
.
J Clin Oncol
.
2018
;
36
(
22
):
2259
-
2266
.
32.
Vitolo
U
,
Trněný
M
,
Belada
D
, et al
.
Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma
.
J Clin Oncol
.
2017
;
35
(
31
):
3529
-
3537
.
33.
FDA/CDER/Purdie FP. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Silver Spring, MD: Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration;
2015
:27.
34.
Yoo
DH
,
Suh
C-H
,
Shim
SC
, et al
.
Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial
.
BioDrugs
.
2017
;
31
(
4
):
357
-
367
.
35.
Kim
WS
,
Buske
C
,
Ogura
M
, et al
.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
.
Lancet Haematol
.
2017
;
4
(
8
):
e362
-
e373
.
36.
Ogura
M
,
Sancho
JM
,
Cho
S-G
, et al
.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
.
Lancet Haematol
.
2018
;
5
(
11
):
e543
-
e553
.
37.
McBride
H
,
Maher
G
,
Sweet
H
,
Foltz
I
,
Kuhns
S
.
Functional similarity of proposed biosimilar ABP 798 with rituximab [abstract]
.
Blood
.
130
(
suppl 1
):
5001
.
38.
Sharman
J
,
Liberati
AM
,
Silva
RS
, et al
.
A randomized, double-blind efficacy and safety study of PF-05280586 (a potential rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low tumor burden follicular lymphoma (LTB-FL) [abstract]
.
Blood
.
2018
:
132
(
suppl 1
):
394
.
39.
Davies
A
,
Merli
F
,
Mihaljević
B
, et al
.
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
.
Lancet Haematol
.
2017
;
4
(
6
):
e272
-
e282
.
40.
Lugtenburg
P
,
Avivi
I
,
Berenschot
H
, et al
.
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
.
Haematologica
.
2017
;
102
(
11
):
1913
-
1922
.
41.
Assouline
S
,
Buccheri
V
,
Delmer
A
, et al
.
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
.
Br J Clin Pharmacol
.
2015
;
80
(
5
):
1001
-
1009
.
42.
Gribben
JG
,
Fowler
N
,
Morschhauser
F
.
Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma
.
J Clin Oncol
.
2015
;
33
(
25
):
2803
-
2811
.
43.
Leonard
JP
,
Trneny
M
,
Izutsu
K
, et al
;
AUGMENT Trial Investigators
.
AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
.
J Clin Oncol
.
2019
;
37
(
14
):
1188
-
1199
.
44.
Andorsky
D
,
Coleman
M
,
Yacoub
A
, et al
.
Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: interim analysis of initial phase of MAGNIFY phase iiib study of R2 followed by maintenance in relapsed/refractory indolent NHL
.
J Clin Oncol
.
2018
;
36
(
suppl 15
). Abstract 7516.
45.
Morschhauser
F
,
Fowler
NH
,
Feugier
P
, et al
;
RELEVANCE Trial Investigators
.
Rituximab plus lenalidomide in advanced untreated follicular lymphoma
.
N Engl J Med
.
2018
;
379
(
10
):
934
-
947
.
46.
Nowakowski
GS
,
Chiappella
A
,
Witzig
TE
, et al
.
ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
.
Future Oncol
.
2016
;
12
(
13
):
1553
-
1563
.
47.
Vitolo
U
,
Witzig
TE
,
Gascoyne
RD
, et al
;
ROBUST study investigators. ROBUST: first report of phase III randomized study of lenalidomide/RCHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
.
Hematol. Oncol
.
2019
;
37
(
suppl 2
):
36
-
37
.
48.
Advani
R
,
Flinn
I
,
Popplewell
L
, et al
.
CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma
.
N Engl J Med
.
2018
;
379
(
18
):
1711
-
1721
.
49.
Russ
A
,
Hua
AB
,
Montfort
WR
, et al
.
Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review
.
Blood Rev
.
2018
;
32
(
6
):
480
-
489
.
50.
Nagorsen
D
,
Bargou
R
,
Ruttinger
D
,
Kufer
P
,
Baeuerle
PA
,
Zugmaier
G
.
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
.
Leuk Lymphoma
.
2009
;
50
(
6
):
886
-
891
.
51.
Löffler
A
,
Kufer
P
,
Lutterbüse
R
, et al
.
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
.
Blood
.
2000
;
95
(
6
):
2098
-
2103
.
52.
Bannerji
R
,
Arnason
JE
,
Advani
R
, et al
.
Emerging clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and other B-cell non-Hodgkin lymphoma (B-NHL) subtypes [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
1690
.
53.
Budde
LE
,
Sehn
LH
,
Assouline
S
, et al
.
Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
399
.
54.
Hutchings
M
,
Iacoboni
G
,
Morschhauser
F
, et al
.
CD20-Tcb (RG6026), a novel “2:1” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma: preliminary results from a phase I first in human trial [abstract]
.
Blood
.
2018
;
132
(
suppl 1
):
226
.
55.
Shah
NN
,
Maatman
T
,
Hari
P
,
Johnson
B
.
Multi targeted CAR-T cell therapies for B-cell malignancies
.
Front Oncol
.
2019
;
9
:
146
.
You do not currently have access to this content.